Lidocaine iontophoresis for postmastectomy intercostobrachial neuralgia: single-blinded randomized controlled trial
Nancy H. Aboelnour, Walid A. Abouelnaga

Aim
The aim was to investigate the efficacy of lidocaine iontophoresis for neuropathic pain management in intercostobrachial neuralgia after mastectomy.

Design
A single-blinded randomized controlled trial was conducted.

Patients and methods
A total of 40 patients with partial or radical mastectomy were randomly divided into two equal groups: group A (lidocaine iontophoresis) and group B (lidocaine patch). The methods of assessment included visual analog scale (VAS) and pain DETECT questionnaire. Group A received lidocaine iontophoresis day after day for 4 weeks. Group B received lidocaine 5% patch (LIDODERM) onto the painful area for 12 h daily. Treatment program extended for 1 month, whereas evaluation was done before and after treatment.

Results
There was no significant difference between both groups in VAS (0.14) and pain DETECT questionnaire (0.32), before treatment. Comparison between groups after treatment revealed a significant reduction in VAS and pain DETECT questionnaire of group A compared with that of group B (P=0.0001). The percent of reduction in VAS of groups A and B was 86.47 and 61.11%, respectively, whereas the percent of reduction in pain DETECT questionnaire was 76 and 49.57%, respectively.

Conclusion
It was concluded that lidocaine iontophoresis was safe and effective method for intercostobrachial neuralgia management after mastectomy in expression of decreasing pain intensity and quality.

Keywords:
lidocaine iontophoresis, mastectomy, pain DETECT questionnaire, visual analog scale

© 2019 Bulletin of Faculty of Physical Therapy | Published by Wolters Kluwer - Medknow

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Regardless of new therapies, management of NP is still complicated, and there is no definite treatment that acts for all cases and their underlying mechanisms. So the rationale of this study was to evaluate the efficacy of lidocaine iontophoresis on intercostobrachial neuralgia after mastectomy, as this study may provide a new localized treatment method in NP management instead of oral medications with their systemic adverse effects.

It was hypothesized that there may be no significant difference between lidocaine iontophoresis and LP in management of NP.

**Patients and methods**

**Patients**

Outpatients with PMPS referred to our outpatient clinic from the National Institution of Oncology in Cairo, Egypt, were eligible for the study if they fulfilled the following requirements: (a) previous partial or radical mastectomy including axillary lymph node dissection for primary breast cancer, with no sign of disease recurrence at the moment of admission to the study; (b) moderate or severe pain of a tight, burning, or constricting nature, persisting for 3 months or more following the surgery, in the anterior chest wall, and/or axilla, and/or medial upper arm; (c) altered sensitivity of the skin (dysesthesia, allodynia, and hypohyperesthesia) in the painful area; (d) absence of other causes of arm pain (brachial plexus neuropathy owing to radiotherapy or to lymphedema entrapment, cervical radiculopathy, pericapsulitis of shoulder joint, and carcinomatous infiltration); (e) provided informed consent to participate in the study; (f) no topical agent used 7 days before trial onset; and (g) no new oral agent to be used during the trial.

Patients were excluded if (a) open skin lesions were present in the area of pain; (b) other skin conditions were present in the affected area; (c) severe depression with voiced suicidal intent was present; and (d) another unrelated significant pain problem existed.

**Sample size determination**

Sample size calculation was performed before the study using G*POWER statistical software (version 3.1.9.2; Franz Faul, Universitat Kiel, Germany). Visual analog scale (VAS) was the primary outcome. The calculation revealed that the appropriate sample size for this study was \( n = 40 \). Calculations were made using \( \alpha = 0.05 \), \( \beta = 0.2 \) and large effect size and allocation ratio \( N2/N1 = 1 \).

**Design**

This study was a single-blinded randomized controlled trial and was approved by the ethical committee of the Faculty of Physical Therapy, Cairo University, NO:P.T.REC/012/001855. All patients were given an informed consent, and after inclusion, the patients were randomly divided into two equal groups.

Randomization process was applied using the envelope method. After patients agreed to participate in the study, cards with either ‘lidocaine iontophoresis’ or ‘LP’ written on them were sealed in envelopes; these envelopes were given to a staff physical therapist who was blinded to this study, and she/he picked one envelope. Depending on which card was selected, participants were allocated to their respective group. Group A comprised 20 patients who received lidocaine iontophoresis and group B comprised 20 patients who received LP.

The examining physical therapist was not involved in the randomization process and remained unaware of the treatment allocation. Patients were instructed not to reveal their treatment allocation to the physical therapists during assessment. Appointments for starting the treatment were arranged, and the treatment was started within one week of randomization.

**Treatment**

A total of 40 female patients were randomized to either lidocaine iontophoresis (group A) or LP 5% (group B). Patients in group A received lidocaine iontophoresis (Phyaction 787; Uniphy BV, Netherland) day after day for 4 weeks. A cotton pad was soaked with 10 ml of 2% lidocaine with 0.9 sodium chloride, which acts as an indifferent solution. The cotton pad then was placed over the painful area and then electrode was placed over the pad and fixed with a thin, self-adhesive paper sheet. Iontophoresis current was 4 mA electrical current to the cathode for 10 min to deliver a dose of 40 mA/min.

Patients in group B were instructed to apply up to four lidocaine patch 5% (LIDODERM) onto the painful area for 12 h daily, always either during the day or at night. A maximum number of four patches could be applied to remain below 1/10 of the lidocaine blood levels that generate cardiac dysrhythmia. LP consisted of an adhesive material containing lidocaine 5% (700 mg/patch) applied to a non-woven polyester felt backing and covered with polyethylene terephthalate film-release liner and measures 10×14 cm.
Pain intensity was measured by a VAS and pain DETECT questionnaire. VAS is considered the ‘gold standard’ technique and is used particularly in pain-related research. It is consisted of a 10-cm line marked ‘no pain’ at one end and ‘pain as bad as it could be’ at the other. The patient marked the line according to the pain intensity experienced at that particular time [10].

The pain DETECT questionnaire consists of seven questions that address the quality of NP symptoms; it was completed by the patient, and no physical examination was required. The first seven questions ask about the gradation of pain, scored from 0 to 5 (never=0, hardly noticed=1, slightly=2; moderately=3, strongly=4, and very strongly=5). Question 8 asks about the pain course pattern, scored from −1 to 2, depending on which pain course pattern diagram is selected. Question 9 asks about radiating pain, answered as yes or no, and scored as 2 or 0, respectively.

The final score between −1 and 38 indicates the likelihood of a NP component. A score of less than or equal to 12 indicates that pain is unlikely to have a neuropathic component (<15%), whereas a score of greater than or equal to 19 suggests that pain is likely to have a neuropathic component (>90%). The Arabic version of this questionnaire is considered a simple validated and reliable assessment tool for NP components [11].

Statistical analysis
Descriptive statistics and t-test were conducted for comparison of participant characteristics between groups. Normal distribution of data was checked using the Shapiro–Wilk test for all variables. Levene’s test for homogeneity of variances was conducted to test the homogeneity between groups. t-Test was conducted to compare mean values of VAS and pain DETECT questionnaire between both groups; and paired t-test was conducted to compare between pretreatment and post-treatment mean values of the measured variables in each group. The level of significance for all statistical tests was set at P less than 0.05. All statistical tests were performed through the statistical package for the social sciences (SPSS) version 19 for windows (IBM SPSS, Chicago, Illinois, USA).

Results
A diagram of the patients’ randomization in the study is shown in Fig. 1. A total of 52 female patients were admitted and assessed for eligibility, twelve of them were excluded as they did not meet the required criteria, whereas 40 patients were found to be eligible to participate in the study. All patients completed the treatment program without withdrawal.

Participant characteristics
Table 1 showed the participant characteristics of both groups. There was no significant difference between both groups in the mean age, weight, and height (P>0.05).

Within group comparison
There was a significant decrease in VAS and pain Detect after treatment in group A compared with that pretreatment (P=0.0001). The percent of decrease in VAS and pain DETECT questionnaire was 86.47 and 76%, respectively (Table 2, Figs 2 and 3).

Regarding group B, there was a significant decrease in VAS and pain Detect after treatment in group B compared with that before treatment (P=0.0001). The percent of decrease in VAS and pain DETECT questionnaire was 61.11 and 49.57%, respectively (Table 2, Figs 2 and 3).

Comparison between groups
There was no significant difference between both groups in VAS and pain Detect before treatment (P>0.05). Comparison between groups after treatment revealed a significant decrease in VAS and pain DETECT questionnaire of group A compared with that of group B (P=0.0001) (Table 3, Figs 2 and 3).

Discussion
Iontophoresis is a noninvasive therapeutic modality that allows permeation of ionized drug molecules through the skin by applying constant low-voltage electrical current. Many drugs can be transmitted via iontophoresis involving analgesics, anti-inflammatory medications, and steroids [12]. Drug transmission via iontophoresis has many characteristics, as it is considered a safe, nonpainful and noninvasive modality. It eliminates systemic drug adverse effects and increases the therapeutic efficacy of the drug by bypassing hepatic first-pass metabolism. It introduces few amounts of drug in comparison with other drug delivery modalities and also reduces the dosage frequencies and improves patient compliance [13].

Dealing with and treating NP is a sophisticated process and usually needs different specializations. Various publications and clinical guidelines prompt topical lidocaine to be used as a first-line choice when
Lidocaine iontophoresis for postmastectomy intercostobrachial neuralgia

Aboelnour and Abouelnaga

**Table 1 Comparison of participant characteristics between groups A and B**

| Characteristic      | Mean±SD   | MD   | t Value | P value |
|---------------------|-----------|------|---------|---------|
| Age (years)         | 48.05±4.52| 47.3±5.06 | 0.75   | 0.49    | 0.62    |
| Weight (kg)         | 82.33±5.01| 81.93±9.27 | 0.4    | 0.2     | 0.83    |
| Height (cm)         | 172.16±5.76| 171.83±9.69 | 0.33   | 0.16    | 0.87    |

**Lidocaine iontophoresis can be reinforced by 20–60 folds comparing with that of topical use [28].**

Lidocaine works via blocking of abnormally working (sensitive) sodium channels of nociceptors located in dermis [29], thus stabilizing the membrane potential of treating localized NP [14–26]. Lidocaine iontophoresis is a substitutional procedure to deliver lidocaine through the skin by using a device which employs an electrical current to mobilize an ionized form of lidocaine toward the skin and subcutaneous tissue [27]. It was found that the permeation of the drug by using iontophoresis can be reinforced by 20–60 folds comparing with that of topical use [28].
abnormally excited Aδ and C fibers producing a decrease of their ectopic flow and subsidiary pain alleviation [29–32]. Lidocaine can be efficient in nociceptors-deprived skin [33,34], as the neighboring Aβ afferent to the affected nociceptors within the affected nerve can be targeted by lidocaine. This may cause blockage of sodium channels and thus decrease ectopic flow and decrease spontaneous pain and allodynia [29].

Sasao and Ozawa [35] investigated the effect of lidocaine iontophoresis in patients with postherpetic neuralgia (PHN). They carried out this study on more than 1000 patients with PHN (mean duration of PHN was 30.6 months). They found that after an average of 3.8 sessions of treatment, two-thirds of these patients were improved by 40–100%. Ozawa et al. [36] carried out a follow-up study to investigate clinical efficacy of lidocaine and methylprednisolone iontophoresis on PHN. Follow-up of 179 patients with PHN for 1–5 years after completion of treatment revealed that pain stayed without changing or decreasing comparing with pain scores recorded upon the end of treatment in 94.4% of patients. In spite of 42.6% of patients still keeping on some therapy, 90.9% were found to be able to take care of themselves. The authors concluded that iontophoresis has short-term and long-term effects and can be a beneficial clinical treatment option.

Several controlled clinical trials have demonstrated the efficacy and safety of the LP 5% for the treatment of NP. Hans et al. [37], conducted a prospective, open, nonrandomized study to investigate the effect of LP 5% on postoperative/post-traumatic neuropathic chronic cutaneous pain. A total of 40 patients were included, and the results showed that ∼52.5% of the patients improved by lidocaine treatment, as the mean VAS score decreased from 7.225±1.209 at initial evaluation to 4.625±1.675 at the end of treatment (4 weeks). Garzón-Rodríguez et al. [38] used lidocaine 5% patches as a co-analgesic in cancer pain, and they concluded that lidocaine 5% patch has a beneficial short-term effect in the management of neuropathic cancer pain associated with allodynia whether the cause of pain was painful scar or chest wall tumor.
Delorme et al. [39] performed a retrospective, observational study to determine the efficacy and safety of using 5% lidocaine-mediated plaster in the management of refractory chronic NP by reviewing the medical record of 467 patients. There was more than one year between the time of onset and referral in two-thirds of cases. Approximately 78.1% of patients had a peripheral NP after surgery, whereas 23% had a post-traumatic pain. The results showed decrease in both pain intensity and analgesics consumption. The study demonstrated an excellent safety profile of 5% lidocaine-medicated plaster and supported its efficacy in management of chronic NP.

In a two-stage adaptive, open-label, randomized study comparing the effectiveness and safety of 5% lidocaine-mediated plaster with pregabalin in PHN and diabetic polyneuropathy (DPN), 300 patients were enrolled (96 with PHN and 204 with painful DPN). The results showed that there was an improvement in pain scores with 5% lidocaine-mediated plaster than with pregabalin in PHN (corresponding numbers for the per protocol set, PPS: 62.2 vs. 46.5%); both treatments were comparable in DPN (PPS: 66.7 vs. 69.1%). Moreover, 5% lidocaine-mediated plaster demonstrated greater quality of life improvement in patients with PHN; both treatments were comparable in patients with DPN. Both treatments decreased the severity of allodynia. It was concluded that in patients with PHN, 5% lidocaine-mediated plaster showed better effect in comparison with pregabalin, whereas in DPN, both treatments showed comparable effect supporting the use of 5% lidocaine-mediated plaster as a first-line choice in management of NP [30].

Galer et al. [40] enrolled 96 patients with PHN in a prospective, vehicle-controlled, double-blind, randomized study to evaluate the effectiveness of LP 5% in distinguished qualities of NP that are common in different neuropathic conditions by using NP scale. It was concluded that LP 5% improved all common pain qualities (i.e. ‘sharp’, ‘hot’, ‘dull’, and ‘deep’) which are believed to be nondermal and nonsuperficial in nature after the application of LP 5% for 3 weeks. Uzaraga et al.
[41] conducted a pilot study to evaluate the efficacy of topical amitriptyline, ketamine, and lidocaine (AKL) on NP caused by radiation dermatitis using Washington Neuropathic Pain Scale. The patients were instructed to apply AKL gel three times per day from the initial evaluation for 2 weeks after radiation. It was concluded that AKL decreased several measures of NP and can be considered as a safe and effective treatment option in treating NP following radiation dermatitis.

In our study, we reported a significant decrease in VAS and pain DETECT questionnaire of group A compared with that of group B ($P=0.0001$). The results showed that lidocaine iontophoresis is more effective than LP in intercostobrachial neuralgia management. However, this study is limited by small sample size and short duration of the treatment program, so more studies are required with larger sample to investigate and confirm the effectiveness of lidocaine iontophoresis in NP management considering the optimal dose and frequency. Follow-up study is also necessary to reveal the long-term effects of iontophoresis and recurrence of pain.

Conclusion
Our observations are in agreement with the international guidelines that support topical lidocaine as a first-choice treatment for localized peripheral NP. The results of our study showed that topical lidocaine applied either by iontophoresis or patch has a clear and significant effect on NP in expression of decreasing pain intensity and quality, and also the results revealed that lidocaine iontophoresis is more effective and superior to LP, suggesting that lidocaine iontophoresis is recommended as a first-choice treatment in ICN.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1 Yamitsky D, Eisenberg E. Neuropathic pain: between positive and negative ends. Pain Forum 1996; 7:241–242.
2 Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 2011; 152:2836–2843.
3 Finnerup NB, Haroutounian S, Kamberman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016; 157:1599–1606.
4 Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain 2003; 104:1–13.
5 Cavallei G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 2002; 38:1832–1837.
6 Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003; 25:12–17.
7 Nelson DA, Landau WM. Intrathecal methylprednisolone for postherpetic neuralgia. N Engl J Med 2001; 344:1019–1022.
8 Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2009; 4: CD007393.
9 Katz NP, Gammaitoni AR, Davis MW, Dworkin RH. Liddochain Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med 2003; 3:324–332.
10 Bendinger T, Plunkett N. Measurement in pain medicine. BJU Education 2016; 16:310–315.
11 Abu-Shaheen A, Yousef S, Riaz M, Nofal A, Al-Fayyad I, Khan S, Heena H. Testing the validity and reliability of the Arabic version of the painDETECT questionnaire in the assessment of neuropathic pain. PLoS One 2018; 13:1–13.
12 Wallin NS, Ratliore BS, Jalswai AK. Treatment of palmpalanter hyperhidrosis by iontophoresis. Med J Armed Forces India 2000; 56:27–28.
13 Rai R, Srinivas CR. Iontophoresis in dermatology. Indian J Dermatol Venereol Leprol 2005; 71:236–241.
14 Dubinskiy RM, Kabbani H, El-Chami Z, Bourtewell C, All H. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 63:959–965.
15 Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118:289–305.
16 Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurminko T, et al. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13:1153–1169.
17 Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237–251.
18 Acevedo JC, Amaya A, Casasola Ode L, Chinchilla N, De Giorgis M, Florez S, et al. Guidelines for the diagnosis and management of neuropathic pain: consensus of a group of Latin American experts. J Pain Palliat Care Pharmacother 2009; 23:281–281.
19 O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122:22–32.
20 Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurminko T, European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113–1123.
21 Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85:3–14.
22 Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150:573–581.
23 Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med 2011; 123:134–142.
24 Fernández R, Ahumada M, Muñoz R, Urra X, Yáñez MV, Velasco MO, Aguayo C, et al. Guidelines for definition and management of localized neuropathic pain (LNP): Chilean consensus. Revista El Dolor 2011; 55:12–31.
25 Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for postherpetic neuralgia (PHN): a systematic review. Acta Neurol Scand 2011; 123:295–309.
26 Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance for the management of postherpetic neuralgia in primary care. Postgrad Med 2013; 125:191–202.
27 Kamalioupor H, Ahmadi S. Local infiltration of lidocaine versus lidocaine iontophoresis in pain relief during radial artery cannulation for open heart surgery. IRCTMJ 2007; 9:133–138.
28 Gangarosa LP, Sr, Ozawa A, Ohkido M, Shimomura Y, Hill JM. Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. J Dermatol 1995; 22:865–875.
29 Krumova E, Zeller M, Westermann A, Maier C. Lidocaine patch (5%) produces a selective, but incomplete block of Adelta and C fibers. Pain 2012; 153:273–280.
Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in postherpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009; 25: 1663–1676.

Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health-Syst Pharm 2002; 59:2215–2220.

Baliki MN, Geha PY, Jabakhanji R, Harden N, Schnitzer TJ, Aplarian AV. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol Pain 2008; 4:47.

Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005; 252:677–686.

Herrmann DN, Panoni V, Barbano RL, Pennella-Vaughan J, Dworkin RH. Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies. Muscle Nerve 2006; 33:42–48.

Sasao Y, Ozawa A. Postherpetic neuralgia dermatology practice 10: difficult to treat skin diseases. In: Hashimoto K. et al., editors. Bunkodo, Tokyo. 2000; pp. 110–114 (in Japanese).

Ozawa A, Haruki Y, Ishihata K, Sasao Y, Miyahara M, Sugai J. et al. Follow-up of clinical efficacy of iontophoresis therapy for postherpetic neuralgia (PHN). J Dermatol 1999; 26:1–10.

Hans G, Joukes E, Verhuist J, Vercauteren M. Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases. Curr Med Res Opin 2009; 25:2737–2743.

González-Rodríguez C, Calsina-Berna A, López-Rómboli E, Porta-Sales J. Lidocaine 5% patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer 2013; 21:3153–3158.

Delorme C, Navez ML, Legout V, Deleens R, Moyse D. Treatment of neuropathic pain with 5% lidocaine-medicated plaster: five years of clinical experience. Pain Res Manag 2011; 16:259–263.

Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle controlled, 3-week efficacy study with use of the Neuropathic Pain Scale. Clin J Pain 2002; 18:297–301.

Uzaraga I, Gerbis B, Holwerda E, Gillis D, Wai E. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. Support Care Cancer 2012; 20:1515–1524.